ACETAZOLAMIDE FOR INJECTION, USP 500 MG — DIN 02358328
ACETAZOLAMIDE (ACETAZOLAMIDE SODIUM) : 500 MG · STERIMAX INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is ACETAZOLAMIDE FOR INJECTION, USP?
ACETAZOLAMIDE FOR INJECTION, USP 500 MG contains ACETAZOLAMIDE (ACETAZOLAMIDE SODIUM) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02358328, held by STERIMAX INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 19-Jun-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ACETAZOLAMIDE FOR INJECTION, USP used for?
Adjunctive treatment of: edema (CHF, drug-induced); centrencephalic epilepsies; chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Acetazolamide cost around the world?
Acetazolamide is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 2 | 23 | USD███.██ |
| Saudi Arabia | public | 6 | 7 | SAR███.██ |
| United Arab Emirates | public | 1 | 3 | AED███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 1 | 1 | EUR███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
44 pack listings across 20 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Acetazolamide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Acetazolamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Acetazolamide, across 11 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 1 | 1 | ACETAZOLAMIDE | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | ACETAZOLAMIDE FOR INJECTION USP | Sourceable in Canada |
| STORZ, DIVISION OF WYETH-AYERST CANADA INC. | 3 | 0 | DIAMOX PWS 500MG/VIAL, DIAMOX SRC 500MG, DIAMOX TAB 250MG | No marketed DIN |
| WYETH-AYERST CANADA INC. | 2 | 0 | DIAMOX IV 500MG, DIAMOX TABLETS 250MG | No marketed DIN |
| NOVOPHARM LIMITED | 1 | 0 | NOVO-ZOLAMIDE TAB 250MG | No marketed DIN |
| STERIMAX INC | 1 | 0 | ACETAZOLAMIDE FOR INJECTION, USP | No marketed DIN |
| VALEANT CANADA LP / VALEANT CANADA S.E.C. | 1 | 0 | ACETAZOLAM | No marketed DIN |
| WYETH CANADA | 1 | 0 | DIAMOX SEQUELS | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 500 mg vials. |
| Storage | Store drug product at 15°-30°C. Reconstituted solution should be stored in refrigerator at 2°-8°C and used within 12 hours. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Acetazolamide |
|---|---|
| ATC code | S01EC01 |
| AHFS class | 52:40.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02358328 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2358328 |
| Brand name | ACETAZOLAMIDE FOR INJECTION, USP |
| Generic / active ingredient | ACETAZOLAMIDE (ACETAZOLAMIDE SODIUM) : 500 MG |
| Market authorization holder | STERIMAX INC |
| Health Canada schedule | Prescription |
| ATC code | S01EC01 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01EC |
| Current status | DORMANT |
| Status date | 19-Jun-2025 |
| Original market date | 2010-12-03 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Reconstitute 500mg vial with 5mL Sterile Water. IV route preferred. Edema: 250-375mg daily. Epilepsy: 8-30mg/kg daily. Glaucoma: 250mg-1g per 24 hours in divided doses.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to sulfonamides; depressed sodium/potassium levels; kidney/liver disease; suprarenal gland failure; hyperchloremic acidosis; cirrhosis; chronic noncongestive angle-closure glaucoma.
Warnings and precautions
Fatal sulfonamide reactions (SJS, TEN, blood dyscrasias). Risk of idiosyncratic ocular reactions (angle-closure glaucoma). Caution in pulmonary obstruction. Risk of non-cardiogenic pulmonary edema.
Is Acetazolamide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by MARCAN PHARMACEUTICALS INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACETAZOLAMIDE | 250 MG | TABLET | AA PHARMA INC | MARKETED | 00545015 |
| ACETAZOLAMIDE FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02537893 |
| ACETAZOLAM | 250 MG | TABLET | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | 00295019 |
| DIAMOX IV 500MG | 500 MG | POWDER FOR SOLUTION | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | 02238074 |
| DIAMOX PWS 500MG/VIAL | 500 MG | POWDER FOR SOLUTION | STORZ, DIVISION OF WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | 02039249 |
| DIAMOX SEQUELS | 500 MG | CAPSULE (SUSTAINED-RELEASE) | WYETH CANADA | CANCELLED POST MARKET | 02238073 |
| DIAMOX SRC 500MG | 500 MG | CAPSULE (SUSTAINED-RELEASE) | STORZ, DIVISION OF WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | 02039230 |
| DIAMOX TAB 250MG | 250 MG | TABLET | STORZ, DIVISION OF WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | 02039222 |
| DIAMOX TABLETS 250MG | 250 MG | TABLET | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | 02238072 |
| NOVO-ZOLAMIDE TAB 250MG | 250 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | 00488275 |
2 · Same class — other molecules in ATC S01EC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dorzolamide | APO-DORZOLAMIDE · DORZOLAMIDE · DORZOLAMIDE EYE DROPS BP · DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION · +7 more | 13 | 3 | Yes |
| Acetazolamide | ACETAZOLAM · ACETAZOLAMIDE · ACETAZOLAMIDE FOR INJECTION USP · ACETAZOLAMIDE FOR INJECTION, USP · +7 more | 11 | 2 | Yes |
| Methazolamide | METHAZOLAMIDE · NEPTAZANE TABLETS 25MG · NEPTAZANE TABLETS 25MG USP · NEPTAZANE TABLETS 50MG | 5 | 1 | Yes |
| Brinzolamide | AZOPT · SANDOZ BRINZOLAMIDE | 2 | 1 | Yes |
| Brinzolamide, Combinations | SIMBRINZA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC S01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| S01ED | Betaxolol · Betaxolol, Combinations · Levobunolol · Levobunolol, Combinations · Timolol · +1 more | 107 | 28 |
| S01EE | Bimatoprost · Latanoprost · Latanoprostene Bunod · Tafluprost · Travoprost · +1 more | 40 | 19 |
| S01EA | Apraclonidine · Brimonidine · Dipivefrine · Epinephrine | 28 | 10 |
| S01EB | Acetylcholine · Carbachol · Ecothiopate · Pilocarpine · Pilocarpine, Combinations | 65 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACETAZOLAMIDE FOR INJECTION, USP called?
The same molecule, Acetazolamide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Acetazolamide | Latin | Bahrain, Lebanon, Saudi Arabia |
| Diamox | Latin | Australia, Morocco |
| ACETAZOLAMIDE MARCAN | Latin | Bahrain |
| Acetrajex | Latin | Saudi Arabia |
| Azomid | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.